Cyclosporine A (CsA) effectively controls psoriasis, however, its long-term continuous use is not recommended. This study aims to evaluate the efficacy and tolerability of week-end CsA microemulsion for the reduction of relapse rate in patients with chronic plaque psoriasis who had achieved clinical remission following continuous CsA therapy. The PREWENT (Psoriasis Relapse Evaluation with WeekEnd Neoral Treatment) study was a 24-week, randomized, double-blind, multicenter study, carried out in 22 Italian hospital or university Dermatology units. CsA was discontinued for 8 days previous to the patients being randomized to oral CsA 5 mglkglday or placebo for two consecutive days/week, for a total period of 24 weeks. The primary endpoint was clinical success rate at week 24, defined as the proportion of patients with no clinical worsening (no relapse or a Psoriasis Area and Severity Index [PASI] <75% of pre-treatment PASI). A total of 162 patients were randomized to CsA and 81 to placebo. Clinical success rates at 24 weeks were 66.9% and 53.2% with CsA and placebo, respectively (p = 0.072). Time to first relapse was significantly prolonged with CsA versus placebo (p = 0.023), and PASI was significantly lower from weeks 4 to 16 in CsA recipients. In patients with moderate-severe psoriasis, the clinical success rate was significantly increased with CsA compared to placebo (69.9% vs 46.3%; p = 0.011), and significantly lower increases in PASI were observed from week 4 to week 24 (p < 0.05 vs placebo). CsA was well tolerated, with no differences in mean blood creatinine or blood pressure between CsA and placebo recipients. However, the high withdrawal rate (22.2% of randomized patients), which was not related to side effects, may have led to an overestimation of efficacy, but the study had a good statistical power (88% greater than that observed in similar studies, i.e, 80%). Week-end CsA administration was shown to prolong safely and effectively the time to first relapse in psoriasis patients.
However, the chronic nature ofthe disease leads to the continuous search for new, better tolerated treatment regimens. Intermittent courses have been compared with continuous treatment, showing controversial results: although tolerability was overall improved, efficacy was not always comparable to that achieved with the continuous regimen (7) (8) .
In clinical practice, CsA has a high efficacy rate and can quickly induce remission. The most commonly adopted CsA regimen in psoriasis consists of intermittent courses of continuous administration for a few months, in order to minimize the side effects directly related to treatment duration. Following treatment discontinuation, disease remission is maintained for 12-24 weeks in about 30% of patients (9) .
Some immunosuppressive drugs, such as corticosteroids, cyclophosphamide and methotrexate, have been shown to be effective when administered as pulse therapy; pulse administration improves also the tolerability profile of these drugs (10) (11) (12) (13) .
Preliminary data on treatment regimens based on the administration of CsA every 12 hours for 2, 3 or 4 days/week are encouraging in terms of efficacy and tolerability for both the induction of psoriasis remission and the maintenance of clinical improvements (14) (15) (16) (17) .
In order to improve the balance between the effectiveness of CsA in maintaining long-term remission and the safety of a prolonged treatment, the PREWENT (Psoriasis Relapse Evaluation with Week-End Neoral Treatment) study was designed to evaluate the efficacy and tolerability of CsA microemulsion administered on two consecutive days weekly, for a total of 24 weeks, in comparison with placebo. The primary endpoint was the relapse rate in patients with chronic plaque psoriasis who had achieved remission during a continuous therapy with CsA.
MATERIALS AND METHODS

Patients and study design
This 24-week, randomized, double-blind, placebocontrolled, parallel group multicenter study, which involved 22 Italian dermatology Units, consisted of a screening phase and a treatment phase. The study was conducted between May 2006 (starting date of the study) and November 2007 (date of the last data collection for the primary outcome). The study was submitted to the National Institute of Health (NIH) and details are reported in clinicaltrials.gov (NCT00438360). Ethics committee approval and written informed consent were obtained before the initiation of the trial. The study was conducted in accordance with the Declaration of Helsinki principles.
At the screening visit, patients of either gender, aged 18-65 years, with a diagnosis of chronic plaque psoriasis, on continuous treatment with any dose regimen of CsA for 8 to 16 weeks (induction treatment), were selected if they had achieved clinical remission, defined as a reduction 2:75% of the Psoriasis Area and Severity Index (PASI) score measured before starting CsA treatment (18) (19) . Main exclusion criteria were body weight > 11 0 kg, uncontrolled arterial hypertension, malignancies, infections and severe hematological, immunological, cardiovascular metabolic or neurological disorders. However, patients with diabetes and hypercholesterolaemia were not excluded if they were receiving treatment for these conditions.
In the enrolled patients, CsA was discontinued and subjects entered the screening phase. During this phase, blood count examinations were performed in order to evaluate the hematological status, and renal and liver function. After 8 ± 2 days from the screening visit, patients still in remission who had normal laboratory parameters were randomly allocated in a 2: I ratio to receive either oral CsA microemulsion treatment 5 mglkg/day (in two divided daily doses) or placebo for two consecutive days (on weekends) per week, for a total period of 24 weeks.
Each package of the study drug contained a two-part label, each with a unique randomization number matching the treatment specified in the randomization list. One part ofthe label was attached to the Drug Label Form containing the patient number immediately prior to dispensing.
Clinical outcome measures
The primary endpoint was the relapse rate at 24 weeks. Relapse was defined as a worsening of psoriasis, defined as a PASI score 2:75% of the score recorded before the initiation of the induction treatment phase. Secondary endpoints were time to psoriasis relapse, and change in baseline PASI score, body surface area (BSA) with psoriasis (hence BSA), and itch intensity [subjectively evaluated by visual analog scale (VAS)] versus baseline values. Safety was evaluated by recording the onset of adverse events (AEs), and by physical examination, vital signs measurement, and laboratory examinations. All adverse events are summarized by presenting, for each treatment group, the number and percentage of patients having any adverse event. Control visits were carried out at 4, 8, 16 and 24 weeks after randomization.
Statistical analysis
The sample size was calculated based on the chi-square test as it was not possible to predict covariate effects on response. Assumingan absolutereduction in clinicalrelapse of20% (from 70%to 50%)in 6 monthsin the CsAgroup and an alpha level of 5%, 264 patients were needed to detect a statistical difference between treatmentgroups (randomized in a 2:I ratio with 176 patients in the CsA group and 88 patients in the placebo group). This guaranteed a statistical powerof88%. No adjustments fordrop-outwereconsidered, as all patients were meant to be included in the primary analysis. Calculations were made using NQuery Advisor v5.0 software(Statistical Solutions, USA).
The primary efficacy analysis was conducted on a per-protocol (PP) basis due to the fact that many patients dropped out (30%) after the first visit during summer (8 weeks after randomization, in most cases) and withdrew consent during the first weeks of treatment. The main reason for patient withdrawal was sun exposure, particularly in the South of Italy. Moreover, the particular design of the study resulted, at least in part, in poor treatment compliance. In fact, patients were less willing to continue the treatment as soon as an improvement became evident, thus increasing the drop-out rate; a statistical analysis on drop-out data was not performed. A supportive analysis was also performed on the intentionto-treat (ITT) population. The relapse rate after 24 weeks of treatment was compared between the two treatment groups by a logistic regression analysis model, based on the PASIvalue observed before the treatment attack phase. CsA was considered superior to placebo when P~0.05, according to the Wald test.
All secondary efficacy analyses were performed on the ITT population. The time to clinical relapse was evaluated by survival analysis, using a Cox model based on baseline PASI score (randomization visit) as well as on treatment. CsA was considered superior to placebo when P~0.05, according to the Chi-square test. The changes from baseline PASI, BSA and itch VAS were evaluated by covariance analysis, with baseline values as covariates, with significance set at P~0.05, according to the Wilcoxon test. In case of premature study discontinuation, the last available measurement was compared with baseline.
The safety analysis was carried out on the ITT population; the frequency of AEs, abnormal laboratory evaluations and abnormal systolic and diastolic arterial blood pressure were recorded.
RESULTS
Patient demographics
Ofthe 258 screened patients, 243 were randomized, 162 to CsA microemulsion and 81 to placebo. Fig. I shows patient disposition throughout the study. A total of 160 (98.8%) and 79 (97.5%) patients in the CsA and placebo groups, respectively, represented the ITT population; 4 patients (2 patients in each group) did not take the study drug or placebo and were then excluded from the ITT population. Patient demographics and disease duration were similar between the two groups (Table I ; data are descriptive only). At baseline, the overall mean ratio of PASI scores was similar in patients randomized to CsA microemulsion and in those assigned to placebo (Table I) . At screening, the mean ratio ofPASI scores were 7.7% and 7.4% for the CsA and placebo groups, respectively (median 6.3% and 6.4%). The PP population included 127 (78.4%) and 62 (76.5%) patients in the CsA and placebo groups, respectively; reasons for exclusion from ITT and PP populations are reported in Fig. I .
Efficacy
The proportion of patients in the PP population maintaining clinical success (defined as a PASI <75% that of the pre-induction treatment score) is shown in Fig. 2 (PP population; Wald test, p = 0.0724). At study end, the corresponding relapse rates in CsA and placebo recipients were 33.1 % and 46.8%, respectively.
Time to relapse, as shown in Fig. 3 , was significantly prolonged in patients on CsA, versus those assigned to placebo (Chi-square test; p = 0.0233).
Mean PASI scores were significantly lower in the CsA treatment group than in placebo recipients at weeks 4, 8 and 16 (p :50.01; Table II ), although the difference between CsA and placebo did not achieve statistical significance at week 24 (p = 0.2059).
Mean increases from baseline in BSA and itch intensity measured by VAS were also overall numerically lower in patients treated with CsA in comparison with placebo at all timepoints (Table  III) ; significantly smaller increases were observed for itch intensity in CsA patients at week 4, 8 and 16, when compared with placebo recipients (p < 0.05).
In agreement with the results of the PISCES study (9) , patients who interrupted treatment did not exhibit any episode of rebound.
Safety and compliance
The proportion of patients who experienced at least one AE during the 24 weeks of the study was 38.4% in the CsA group (61/159) and 21.5% in the placebo group (17/79), without statistical difference between groups. Only one serious AE occurred in the CsA group (breast mass), which was judged as unrelated to study treatment. The overall summary ofAEs is reported in Table IV , There were no significant differences in mean blood creatinine levels between treatment groups at any time during the study (data not shown) and similar proportions of patients in CsA and placebo groups experienced elevated blood creatmme levels, defined as a >30% increase from baseline values (5% vs 3.8%). Abnormal blood glucose levels «45 mgldL or >250 mgldL glucose) were not observed. Similarly, no differences in systolic and diastolic blood pressure were reported in either study group (systolic blood pressure: from 123.1 ± 11.3 mmHg at baseline to 124.1 ± 11.1 mmHg at study end in the CsA group, and from 123.4 ± 10.0 mmHg at baseline to 124.9 ± 11.2 mmHg at study end in the placebo group; diastolic blood pressure: from 78.6 ± 7.7 mmHg at baseline to 78.6 ± 7.6 mmHg at study end in the CsA group, and from 77.9 ± 7.8 mmHg at baseline to 79.7 ± 7.3 mmHg at study end in the placebo group).
Compliance (defined as the number of CsA or placebo capsules taken divided by the number of expected capsules x 100; mean) were 96.4 ± 8.1% for CsA recipients (n = 158) and 95.2 ± 10.2% for placebo recipients (n = 79). Approximately 95% of patients in the CsA group and 92.4% of those assigned to placebo had~80% compliance.
Post-hoc analysis
The clinical success rates, according to PASI disease severity tertiIe, were analyzed post-hoc to estimate the difference between treatment groups according to disease severity at entry before continuous induction treatment with CsA. Patients were stratified by pre-treatment PASI score tertiles (where tertile I includes all patients with a baseline PASI value <12 for CsAgroup and <12.5 for placebo group; tertile II includes all patients with a baseline PASI value between 12-19 for CsA group and 12.5-19.6 for placebo group; and tertile III includes all patients with a baseline PASI value> 19 for CsA and >19.6 for placebo) and an analysis of mean PASI scores observed at each time-point was performed. The mean PASI scores were compared by tertiIe for each treatment group using a last observation carried forward (LOCF) approach.
By stratifying patients by PASI before treatment initiation, the differences in efficacy observed between the groups become clearer, even if it must be pointed out that these results are retrieved from a post-hoc analysis and must therefore be interpreted with particular caution. The time course of PASI scores during the study analyzed by disease severity tertiles (Fig. 4) shows that the prevention of PASI increase obtained with CsA versus placebo was more evident in the intermediate tertiIe (tertile II) . Patients belonging to tertiles I and II maintained a mean PASI score of 5 points below the pre-treatment value over 6 months of CsA week-end treatment (Fig. 4A) . By comparison, in the placebo group, only patients with lower pre-treatment PASI scores (tertiIe I) maintained a mean PASI score of 5 points lower than the pre-treatment score after 6 months (Fig. 4B) .
In patients belonging to tertiIe I and II, weekend CsA therapy was significantly more effective than placebo: mean PASI scores at each time point in tertiles I and II separately and combined (LOCF, PP population) were significantly lower with CsA treatment versus placebo from week 4 up to study end (p < 0.05 at all time points; Fig. 5 ). CsA prevented an increase in PASI scores during the whole 6-month maintenance phase in patients belonging to tertiIe I and II, whereas patients on active treatment with very severe disease (tertiIe III) showed a progressive increase in PASI scores, similar to that observed with placebo (data not shown). This difference in efficacy between treatment groups was confirmed by the significant reduction in relapse rate observed following 6-month CsA treatment in patients with lower PASI score at pre-treatment (i.e. excluding those in tertiIe III): in these patients, relapse occurred in 30.1% of CsA recipients and 53.7% of placebo recipients (chi square test; p = 0.0110). However, no differences in relapse rate were observed in the tertile III (CsA: 38.6%; placebo: 33.1%; chi square test; p = 0.6787).
DISCUSSION
CsA has been proven to be effective in inducing remission in patients with psoriasis. However, the maintenance regimen is critical, as it requires a satisfactory balance between efficacy in preventing disease relapse and long-term tolerability.
In this Italian, double-blind, multicenter study, CsA maintenance therapy, administered on weekends for 24 weeks, provided maintenance of remission for up to 6 months in patients who had _~8.~u)JJ~iQ!! ---P la c eb o is limited by its post-hoc nature, suggests that weekend CsA maintenance therapy may be effective for patients belonging to tertiIe II, whereas those belonging to tertiIe I could remain under control without maintenance treatment for up to 6 months following continuous therapy. Conversely, patients with PASI>60, probably require a more intensive maintenance regimen than the one used in this study, as in these subjects, the carryover effect of initial therapy is sustained only for approximately three months. Of note, at the end of the 6-month follow-up period, PASI scores in relapsers were still lower than baseline values, in each tertiIe. Continuous administration of CsA is associated with tolerability issues, such as arterial hypertension and renal impairment, which appears to be dosedependent and treatment-duration related (20) (21) (22) . In order to minimize the risk ofrenal toxicity, short (e.g. l2-week) CsA intermittent courses at a daily dose of 2.5-5.0 mg/kg are recommended (23) . Compared with intermittent therapy, our week-end maintenance schedule of CsA 5 mg/kg/day resulted in reduced total exposure, further contributing to minimize the risk of renal toxicity and other AEs. The tolerability profile of CsA was good and overall comparable to placebo, with only one serious AE, occurring in the CsA group (breast mass, unrelated to study treatment), requiring treatment discontinuation.
Previous studies of intermittent therapy with CsA microemulsion at starting daily doses of2.5-5.0 mg/ kg generally showed higher discontinuation rates, and higher incidence of renal and vascular toxicity than our week-end maintenance schedule (9, 24) .
A high compliance rate of 96.4% for CsA treatment suggests a good acceptability of the weekend regimen; however, the high withdrawal rate [54 (22.2% of randomized patients); 35 CsA and 19 placebo recipients] is a limitation of the study. However, this can be counterbalanced by the high power of the study (88% at the initiation, reduced by 8-10% due to withdrawals, but still in line with the majority of clinical trials). Other limitations include the 6-month study duration, and probably longer trials of up to 1 year may be necessary. In addition, two patients had a baseline PASI >62 before starting continuous therapy, with a likely impact on the efficacy variables resulting in a lower reported efficacy with CsA versus placebo.
However, this study may provide valuable clinical evidence, because it analyzes the effectiveness of CsA in a "real-life" clinical setting, rather than its efficacy in selected patients. This lack of stringent patient selection could mean that the data are likely reliable and unbiased, and can be extrapolated to the clinical setting without particular concerns.
Further trials specifically aimed to evaluate the efficacy of the week-end administration schedule of CsA in patients with moderately severe psoriasis are needed to confirm our results.
